The European Union has imposed a €467 million fine on Teva Pharmaceuticals, one of the leading generic drug manufacturers, for breaching antitrust laws. This decision is part of a broader initiative by EU regulators to ensure fair competition in the pharmaceutical industry. Teva has expressed strong opposition to the ruling, labeling it as “extreme, untested and factually unsupported.” The company plans to challenge the decision and asserts its commitment to complying with antitrust regulations.
For additional details on this development, please refer to the full article available here.